[Edaily Reporter Shin Ha-yeon] On the 17th, Value Finder analyzed #PharosIBio, noting that the company has secured a robust pipeline of innovative new drugs based on its proprietary artificial intelligence (AI) drug discovery platform, “Chemiverse,” and highlighted the potential for global technology licensing (L/O).

Founded in 2016, Paros iBio is an AI-based company specializing in the development of new drugs for rare and intractable diseases. It is using its proprietary AI platform, Chemiverse, to improve upon the high-cost, low-efficiency structure typical of conventional drug development companies, and is pursuing a business model centered on technology licensing to global pharmaceutical companies at the clinical stage. PHI-101, a treatment for acute myeloid leukemia (AML) and the company’s most advanced pipeline candidate, has completed Phase 1 clinical trials and is currently proceeding with global Phase 2 trials and technology transfer efforts.

Jeon Woo-bin, a researcher at Value Finder, commented, “Pharos iBio is driving a paradigm shift in new drug development based on its unique AI platform, Chemiverse,” adding, “The company is currently at a critical inflection point, on the verge of technology transfer—the tangible outcome of AI-driven drug development.”

PHI-101 (rasmotinib), the company’s flagship pipeline, is regarded as a candidate drug capable of overcoming the limitations of gilteritinib, an existing AML treatment. While gilteritinib faces the issue that a significant number of relapsed patients experience disease progression within four weeks of treatment, rasmotinib is designed to address various resistance mutations.

Researcher Jeon explained, “PHI-101 demonstrated superior efficacy compared to existing competitive drugs, recording a complete remission rate (CRc) of 50% and an objective response rate (ORR) of 66.7% in the Phase 1b clinical trial,” adding, “This is particularly significant given that these results were obtained from patients with relapsed or refractory disease who had failed treatment with FLT3 inhibitors.”

Its strengths in terms of safety were also highlighted. He noted, “The incidence of cardiotoxicity—a major issue with existing FLT3 inhibitors—was 0% in the Phase 1 clinical trial,” adding, “This demonstrates a differentiated safety profile compared to competing drugs.”

Expectations are also high for PHI-501, a next-generation pipeline candidate. PHI-501 is a solid tumor treatment based on a dual inhibitor that simultaneously targets pan-RAF and DDR1, and is being developed to overcome resistance issues associated with existing BRAF inhibitors.

Researcher Jeon stated, “PHI-501 is targeting a global market worth over 20 trillion won, including colorectal cancer and melanoma,” adding, “As a next-generation platform-level asset capable of targeting even KRAS and NRAS mutations, we are aiming for a total technology transfer value of 1 trillion won at the Phase 1 clinical trial stage.”

Recently, the company partnered with Kolon Pharmaceutical to begin developing PHI-701, a treatment for non-small cell lung cancer. PHI-701 is being developed as a fourth-generation EGFR inhibitor designed to address resistance to Tagrisso, a global blockbuster lung cancer treatment.

Researcher Jeon explained, “PHI-701 is a dual-mechanism drug that goes beyond simply inhibiting new EGFR mutations to block the survival escape routes of cancer cells,” adding, “Development momentum has been strengthened through our collaboration with Kolon Pharmaceutical and selection for a government-funded project.”

Analysts also suggest that a technology transfer deal is imminent. Pharos iBio will participate as an investor relations (IR) pitching company at BIO USA 2026, taking place in Boston, U.S., from the 22nd to the 25th (local time). At the event, the company plans to introduce its key pipeline candidates—including PHI-101, PHI-501, and PHI-701—to global pharmaceutical companies.

Researcher Jeon noted, “Last year, the company secured the funds necessary for global Phase 2 clinical trials and the development of follow-up pipelines through the issuance of 190억 won worth of convertible bonds (CBs),” and predicted, “Participation in BIO USA could lead to discussions regarding technology transfer with global big pharma companies.” He added, “As the value of the Chemiverse platform and the clinical results of key pipeline candidates continue to accumulate, a revaluation of the company’s market value is expected in the future.”